抗血栓
医学
纤溶酶
静脉血栓栓塞
血栓调节蛋白
内科学
疾病
抗凝血酶
凝结
纤溶
重症监护医学
人口
血栓
D-二聚体
血栓形成
凝血酶
肝素
血小板
化学
环境卫生
酶
生物化学
作者
Yan Jun Li,Qingguang Zhang,H C Wang
出处
期刊:PubMed
日期:2023-10-06
卷期号:57 (10): 1693-1703
被引量:2
标识
DOI:10.3760/cma.j.cn112150-20230507-00353
摘要
Thromboembolism is a crucial part of the global disease burden. It has high incidence, high mortality and disability rates, and the mechanism of occurrence and development is extremely complex. It is difficult to detect the disease in the early stage so that we have trouble with clinical prevention and treatment in general. At present, four items of blood coagulation and D-dimer have been widely used in the evaluation and auxiliary diagnosis of thromboembolism, the monitoring of effect for antithrombotic drugs and other fields. The thrombus biomarkers including thrombin-antithrombin complex (TAT), thrombomodulin (TM), tissue plasminogen activator-inhibitor complex (t-PAIC) and α2-plasmin inhibitor-plasmin complex (PIC) fill the gap of laboratory diagnosis before clinical symptoms appear in some degree. This article aims to explain the current application status of TAT, TM, t-PAIC and PIC in thromboembolism and explore their potential application value, so as to provide a reference for selecting appropriate early monitoring indicators for high-risk population of thromboembolism.
科研通智能强力驱动
Strongly Powered by AbleSci AI